|
Antibody-Drug Conjugate Clinical Trials
3 actively recruiting trials across 1 location
Pipeline
Phase 1/2: 1
Top Sponsors
- Sung-Soo Park2
- MBrace Therapeutics1
Indications
- Cancer3
- Relapsed/refractory High Grade B Cell Lymphoma1
- Diffuse Large B Cell Lymphoma Relapsed1
- Multiple Myeloma, Relapsed1
- Multiple Myeloma (MM)1
Other2 trials
San Francisco, California1 trial
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
UCSF Helen Diller Family Comprehensive Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.